Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis

  Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yasameen Abbas, Nabaa Ihsan, Asal Adnan, Marwa Moayad, Ali AlKazzaz, Avin Maroof, Ali Abdulrahman, Nazar Abdulateef, Mohammad AlOsami, Faiq Gorial, Mohammed Altahhan, Zahraa Almansi, Ali Alnoori
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	University of Baghdad/ Al-Kindy College of Medicine 2024-12-01
Serie:	مجله كليه طب الكندي
Soggetti:	Rheumatoid arthritis Biosimilar Adalimumab
Accesso online:	https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!